Objective: We compared the prognostic factors and clinical characteristics of chronic hepatitis B (CHB) patients who received nucleos(t)ide analogues (NAs) therapy to those who did not.
Method: A total of 315 CHB patients were enrolled in this study and were divided into NA (n=144) and non-NA (n=171) groups based on their therapy.
Results: The risk of hepatocellular carcinoma (HCC) development and mortality in the NA group were significantly lower than those in the non-NA group. Smoking, alcohol abuse, AFP, γ-GTP, and HBV DNA levels were significantly correlated with hepatocarcinogenesis. Alcohol abuse, AFP, γ-GTP, HBV DNA levels and NA treatment were associated with mortality in these patients.
Conclusions: NA therapy reduced the risk of HCC and mortality in CHB patients. Smoking, alcohol abuse, AFP >20 ng/mL, HBV DNA >20,000 IU/mL, and elevated γ-GTP serum concentration were significantly related to poor outcomes.
Keywords: Chronic hepatitis B; Nucleos(t)ide analogues; mortality; prognosis; risk factor; treatment.
Copyright © 2022 by the Association of Clinical Scientists, Inc.